You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

“Yes! We Can End TB." World TB Day is March 24, 2023. Join us in the fight.
I am a:
${ profile.name.substring(0, profile.name.length - 1) }
Request Info
Home / Tests / Healthcare Associated Infections / Xpert Carba-R

Xpert® Carba-R

Xpert® Carba-R is a qualitative, on-demand real-time PCR test for the detection and differentiation of KPC, NDM, VIM, OXA-48 and IMP in 48-minutes

Product Resources MyCepheid Store
Xpert<sup>®</sup> Carba-R
#carousel-featured_content-0 .carousel-layout > .row > div[class*="col"]:nth-child(n + ${ activeRow * colCount + 1 }$), #carousel-featured_content-0 .carousel-layout > .row > div[class*="col"]:nth-last-child(n + ${ storyCount - (activeRow - 1) * colCount + 1}$) { visibility: hidden; max-height: 0px; overflow: hidden; margin-bottom: 0; opacity: 0; left: 30px; }

Diagnostics First

The Need

  • Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs.1
  • Organisms carrying integron and plasmid-encoded carbapenemase enzymes are largely responsible for the rapid spread of carbapenem resistance.2
  • CDC recommends comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms.3
  • Current test methods lack the sensitivity, ease of use, and rapid results required to respond quickly to the threat of carbapenemase-producing organisms.

(1) Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. (http://www.sciencedirect.com/science/article/pii/S0196655316303431);
(2) https://wwwnc.cdc.gov/eid/article/17/10/pdfs/11-0655.pdf;
(3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf

The Solution

Xpert® Carba-R can detect and differentiate the most prevalent carbapenemase gene families in just 48 minutes.

  • Detection and differentiation of high-risk patients with Xpert Carba-R can alert clinicians and infection preventionists (IPs) rapidly to the presence of gene sequences associated with carbapenem non-susceptibility in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
  • Rapid detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy, while testing rectal and perirectal swabs helps IPs design effective infection control measures. Perirectal and rectal swabs are not intended to direct therapeutic strategy.
    • Comprehensive infection control measures should be applied to patients who are colonized or infected with carbapenemase-producing organisms.3

(3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf

Ordering Info

Xpert® Carba-R

Number of Tests: 10

Catalog #: GXCARBAR-10
Back to Top